May 4, 2021
Transformative, leading allogeneic NKT cell platform technology expands Athenex’s cell therapy development capability Platform has broad applications based on transducing NKT…
Welcome To Kuur Therapeutics
Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies.
Our approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called natural killer T cells (NKT cells) and innovative CAR construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors.
The Pipeline
Kuur Therapeutics' ambition is to develop a growing portfolio of allogeneic CAR-NKT products to treat broad populations of patients, across highly prevalent tumors where significant unmet needs remain.
For Patients
Through innovative technologies and collaboration with leading academic institutions, Kuur Therapeutics aims to harness the natural power of the human immune system for the treatment of cancer.
Kuur Therapeutics Partnering
Kuur Therapeutics is actively seeking licensing and partnering opportunities, drawing on global immunotherapy expertise, to explore and advance the therapeutic possibilities for our NKT cell immunotherapy products.
Latest
News
January 21, 2021
Interim data from GINAKIT2 and ANCHOR clinical studies provide evidence of efficacy for Kuur’s chimeric antigen receptor-natural killer T cell (CAR-NKT)…
October 12, 2020
KUR-501 in Nature Medicine HOUSTON, TX– Oct 12, 2020 (BUSINESSWIRE) –Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell…
September 29, 2020
Allogeneic “off-the-shelf” chimeric antigen receptor-natural killer T cell (CAR-NKT) therapy platform could overcome many of the challenges of current autologous CAR-T…
May 15, 2020
HOUSTON – May 15, 2020 – Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment…
March 10, 2020
New investments from IP Group, Baylor College of Medicine (BCM) and Schroeder Adveq Proceeds to fund phase 1 studies in both…